This PQI will discuss the use of belumosudil (Rezurock®) in the management of chronic graft-versus-host disease (cGVHD) after allogeneic hematopoietic cell transplantation. Belumosudil was approved by the United States Food & Drug Administration (FDA) in 2021 with indication for use in patients ≥ 12 years of age with cGVHD after two or more prior systemic therapies.